Skip to content

n-3 PUFAs, Irisin and Maternal Glucose Metabolism From Pregnancy to Postpartum

Effects and Mechanisms of n-3 Polyunsaturated Fatty Acids and Irisin on Maternal Abnormal Glucose Metabolism From Pregnancy to Postpartum

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03023293
Enrollment
1122
Registered
2017-01-18
Start date
2017-03-10
Completion date
2025-12-31
Last updated
2026-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergic Diseases, Child Emotional and Behavioral Problems, Child Growth and Development, Gestational Diabetes Mellitus, Neurodevelopmental Disorders, Postpartum Abnormal Glucose Metabolism

Keywords

n-3 polyunsaturated fatty acids, Dietary patterns, Nutritional status, Irisin

Brief summary

This study aims to investigate the associations of maternal nutritional status during pregnancy and postpartum periods with postpartum abnormal glucose metabolism in Guangzhou pregnant women. Additionally, it seeks to explore the relationships between maternal nutritional status (pre- and postnatal) and offspring health outcomes, including physical growth, neurodevelopment, and common childhood diseases.

Detailed description

Gestational diabetes mellitus (GDM) is a well-established risk factor for the future development of type 2 diabetes in women. However, abnormal glucose metabolism is not exclusive to women with GDM; it can also occur during pregnancy and the postpartum period in those without a history of GDM. Recent studies have indicated that n-3 polyunsaturated fatty acids (n-3 PUFAs) can ameliorate insulin resistance and contribute to the prevention of type 2 diabetes in the general population. Concurrently, the novel myokine irisin has been shown to reduce insulin resistance and plays a significant regulatory role in human glucose metabolism. Ex vivo cellular studies further suggest that n-3 PUFAs can promote irisin expression. Based on this evidence, we hypothesize that n-3 PUFAs may improve postpartum glucose metabolism in women by upregulating irisin expression and subsequently activating the IRS-1/PI3K/AKT insulin signaling pathway. To test this hypothesis, a prospective cohort named Yuexiu Birth Cohort was established. The inclusion criteria were as follows: a) age 20-45 years; b) no pre-pregnancy history of diabetes, cardiovascular disease, thyroid disease, hematological disease, polycystic ovary syndrome, pregnancy-related infections, or psychiatric disorders; c) singleton pregnancy. This natural population cohort included both women with and without GDM. Follow-up data were collected at multiple time points: at 20-28 weeks of gestation (baseline: sociodemographic characteristics, lifestyle factors, anthropometric measurements, and fasting venous blood samples for assessment of glucose and lipid metabolism, erythrocyte membrane n-3 PUFA levels, and irisin levels); at 42 days postpartum (lifestyle and dietary habits, anthropometric measurements, fasting blood glucose and irisin levels); and during child follow-up at 6 months, 2 years, 3-4 years, and 5 years of age (evaluation of child growth, allergic diseases, and neuropsychological development, among other outcomes). The specific research objectives include: a) investigating the longitudinal trajectories of n-3 PUFAs and irisin from pregnancy to the postpartum period and their association with postpartum abnormal glucose metabolism (encompassing all postpartum women, not limited to those with a history of GDM); b) analyzing the correlation between n-3 PUFA and irisin levels; c) assessing the associations between maternal perinatal nutritional status (e.g., n-3 PUFA levels, dietary patterns, and other nutrients) and offspring health outcomes (including growth trajectories, neurodevelopment such as executive function and emotional/behavioral problems, and common diseases such as allergies). This study aims to systematically evaluate the perinatal nutritional status of pregnant women in Guangzhou, elucidate its associations with postpartum abnormal glucose metabolism and offspring health outcomes (growth, neuropsychological development, common diseases, etc.), and unravel the mechanistic link between n-3 PUFAs and irisin in the regulation of glucose metabolism in the general pregnant population. The findings are expected to provide a scientific basis for the prevention of postpartum type 2 diabetes and the promotion of early childhood health development.

Interventions

OTHERNo intervention

This cohort study have any no intervention.

Sponsors

Sun Yat-sen University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
20 Years to 45 Years
Healthy volunteers
Yes

Inclusion criteria

* Age between 20 and 45 years (inclusive). * Singleton pregnancy. * Free from the following pre-pregnancy or pregnancy-related conditions: pregestational diabetes mellitus, cardiovascular disease, thyroid disease, hematological disease, polycystic ovary syndrome, infection during pregnancy, or mental disorder. \- Note: Women who meet all of the above criteria are eligible for the study, regardless of whether they have gestational diabetes mellitus (GDM) or not.

Design outcomes

Primary

MeasureTime frameDescription
Maternal glucose metabolismGestation (24-28 weeks) and, for fasting glucose, also at 42 days postpartum.Maternal glycemic indicators measured during pregnancy (24-28 weeks of gestation) using a 75g oral glucose tolerance test (OGTT), including fasting plasma glucose (FPG), 1-hour post-load glucose, 2-hour post-load glucose, and hemoglobin A1c (HbA1c). Fasting insulin levels are measured by enzyme-linked immunosorbent assay (ELISA), and insulin resistance is estimated using the homeostasis model assessment of insulin resistance (HOMA-IR).
Offspring physical growth and developmentBirth, 6 months, 2 years, 3-4 years, and 5 years of age.Including weight, length/height, head circumference, body mass index (BMI), and growth trajectories from birth to 5 years of age.
Offspring neuropsychological development2 years, 3-4 years, and 5 years of age.Including executive function, emotional and behavioral problems (e.g., Strengths and Difficulties Questionnaire), developmental milestones (e.g., Ages and Stages Questionnaire), and other neuropsychological assessments at 2, 3-4, and 5 years of age.
Offspring allergic diseases6 months, 2 years, and 3-4 years.Including physician-diagnosed or parent-reported eczema, food allergy, atopic dermatitis, allergic rhinitis, and asthma during the first 5 years of life.

Secondary

MeasureTime frameDescription
Maternal postpartum weight42 days postpartum.Postpartum weight (kg) measured at 42 days postpartum.
Maternal postpartum blood pressure42 days postpartum.Postpartum blood pressure (systolic and diastolic, mmHg) measured at 42 days postpartum.
Offspring vision problems3-4 years and 5 years of age.Including visual acuity, refractive errors, or other vision-related conditions assessed at 3-4 and 5 years of age.
Offspring dental caries3-4 years and 5 years of age.Presence of dental caries, decayed/missing/filled teeth (dmft index), and related dental treatment history reported by parents or assessed at 3-4 and 5 years of age.

Countries

China

Contacts

PRINCIPAL_INVESTIGATORLi Cai

Sun Yat-sen University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 16, 2026